Semaglutide, liraglutide, and dulaglutide have demonstrated cardiovascular benefits in clinical trials, with Wegovy (semaglutide 2.4 mg) recently receiving FDA approval for cardiovascular risk reduction in adults with established cardiovascular disease and obesity
Compounded medications referenced in this article - including compounded semaglutide and compounded tirzepatide - are not FDA-approved finished drug products and have not been reviewed by the FDA for safety, effectiveness, or quality before marketing
Dosing and Administration Wegovy is administered as a once-weekly subcutaneous injection, typically starting at a lower dose of 0.25 mg, which can be gradually increased based on individual needs and tolerability
| Curex BCBS Illinois (HCSC) covers Wegovy only where your employer opts in
The difference is mechanism and magnitude
Various preventative techniques explore different approaches